Phaseline

Targets › HLA-B

HLA-B (HLA class I histocompatibility antigen, B alpha chain): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Genitourinary, Oncology; next expected readout Dec 2027.

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. (UniProt, P01889)

Open in Phaseline: the race on HLA-B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCEx Vivo CRISPR-Cas9 Gene Editing of Donor Kidney
CRISPR-Cas9 ribonucleoprotein complexes targeting HLA-A, HLA-B, and CIITA to knock out HLA
HLA-A, HLA-B, CIITAPhase 1End-Stage Renal DiseaseDec 2027
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLCEx Vivo CRISPR-Cas9 Gene Editing of Donor Liver
CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA to create hypoimmunogenic graft
HLA-A, HLA-B, CIITAPhase 1Liver DiseasesDec 2027

Conditions

End-Stage Renal Disease (1) Liver Diseases (1)

Modalities

other (2)

Companies

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC (2)

Related targets

HLA-A (2) CIITA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.